Thursday, 26 March 2026

Allogene’s off-the-shelf CAR-T is nearing early but pivotal study readout 

March 26, 2026
Pharmalot Columnist, Senior Writer
Molly Ferguson/STAT

STAT+ | Allogene's off-the-shelf CAR-T is nearing an early but pivotal study readout

In this week's edition of "Adam's Biotech Scorecard," Adam takes a look at Allogene's study, as well as two biotech CEOs in a very public spat.

By Adam Feuerstein


Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy

This week on the podcast: Lilly's Jake van Naarden is very, very busy, so what does that mean for biotech and pharma?

By Adam Feuerstein and Elaine Chen


STAT+ | Eli Lilly and the 'societal obligation' of GLP-1s

Lilly's success comes with a "societal obligation" to investigate whether GLP-1s can do more than treat obesity and diabetes, said its CMO.

By Elaine Chen



More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments:

Post a Comment